Century Therapeutics, INC Form 4 insider transactions

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 257 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, sold 526 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, sold 5,462 shares of common stock to cover tax withholding obligations related to RSU vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, filed a Form 4 indicating a planned purchase of 35,000 shares of common stock on November 19, 2025, at a weighted average price of $0.4951, with all profits from the transaction to be disgorged to the issuer.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, sold 32,456 shares of common stock to cover tax withholding obligations related to RSU vesting.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 292 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, was granted 762,543 restricted stock units, vesting over two years.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 263 shares to cover tax withholding from restricted stock unit vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, sold 488 shares of common stock to cover tax withholding obligations related to RSU vesting.

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, sold 539 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, was granted 1,587,614 restricted stock units, vesting over two years.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, sold 296 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Kimberly Blackwell, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.60 per share, as disclosed in a recent SEC Form 4 filing.

Century Therapeutics, Inc. Director Joseph Jimenez was granted 44,000 stock options with an exercise price of $0.60, vesting based on continued service.

Alessandro Riva, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.6 per share, as disclosed in a recent SEC Form 4 filing.

Century Therapeutics, Inc. Director Carlo Rizzuto was granted 44,000 stock options with an exercise price of $0.60, vesting on the earlier of June 12, 2026, or the next annual meeting of stockholders.

Century Therapeutics, Inc. Director Daphne Quimi was granted 44,000 stock options with an exercise price of $0.6 per share, vesting over approximately one year.

Cynthia M. Butitta, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.60, vesting over approximately one year.

Century Therapeutics, Inc. Director Timothy P. Walbert has acquired 44,000 stock options at an exercise price of $0.60, vesting by June 12, 2026, or the next annual meeting.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, Inc., sold 4,904 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Century Therapeutics' Chief Operations Officer, Adrienne Farid, sold 552 shares of common stock on June 9, 2025, at $0.622 per share, a non-discretionary transaction to cover tax withholding obligations related to the vesting of restricted stock units.

Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., sold 475 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc., sold 526 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Century Therapeutics CEO Brent Pfeiffenberger sold 29,552 shares of common stock on May 16, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, sold 1,024 shares of common stock on May 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, sold 295 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Morgan Conn, CFO of Century Therapeutics, reports the acquisition of stock options and restricted stock units.

Chad Cowan, Chief Scientific Officer of Century Therapeutics, reports the acquisition of restricted stock units and stock options.

CEO Brent Pfeiffenberger reports the sale of shares to cover tax obligations and the grant of restricted stock units and stock options.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units and received new stock options and restricted stock units.